Escitalopram Side Effects and Management

Introduction to Escitalopram Side Effects

Escitalopram commonly causes side effects including nausea, sleepiness, weakness, dizziness, anxiety, sexual dysfunction, sweating, tremors, decreased appetite, dry mouth, constipation, and insomnia in approximately 63% of patients 1

Symptoms of serotonin syndrome include mental status changes, autonomic instability, neuromuscular symptoms, and gastrointestinal symptoms, and can be fatal 2
Advanced symptoms of serotonin syndrome may include fever, seizures, arrhythmias, and unconsciousness 2
Discontinuation syndrome is characterized by dizziness, fatigue, lethargy, general malaise, headaches, nausea, sensory disturbances, anxiety, irritability, and agitation 3
Escitalopram has a lower risk of discontinuation syndrome compared to paroxetine, fluvoxamine, and sertraline 3
Abnormal bleeding can occur, especially when combined with aspirin or NSAIDs 2
QT prolongation can occur, though escitalopram has less effect on CYP450 enzymes compared to other SSRIs 3

Third-trimester use of SSRIs including escitalopram has been linked to neonatal signs such as crying, irritability, tremors, poor feeding, respiratory distress, sleep disturbance, and hypoglycemia 4, 5, 6
SSRI treatment during pregnancy should be maintained at the lowest effective dose as withdrawal may have harmful effects on the mother-infant dyad 6
Escitalopram is considered a preferred agent for older patients with depression compared to paroxetine and fluoxetine, which should generally be avoided in this population 7, 8

Concomitant use with MAOIs is contraindicated due to risk of serotonin syndrome 3
Caution when combining with other serotonergic drugs, including triptans, opioids, stimulants, and certain over-the-counter medications 3
Escitalopram may interact with drugs that prolong the QT interval 3
Escitalopram has less effect on CYP450 isoenzymes compared to other SSRIs, resulting in a lower propensity for drug interactions 3

Start with lower doses and titrate slowly, especially in patients with anxiety disorders 3
Consider starting with a subtherapeutic "test" dose as initial anxiety or agitation can occur 3

The number needed to harm (NNH) for discontinuation due to adverse effects across SSRIs ranges from 20 to 90, with escitalopram consistently positioned at the most favorable end of this spectrum, indicating fewer patients discontinue because of side effects. 9
Approximately 63 % of individuals treated with second‑generation antidepressants experience at least one adverse effect; escitalopram demonstrates superior gastrointestinal tolerability compared with other SSRIs, reducing the likelihood of nausea‑related discontinuation. 9

Escitalopram carries a significantly lower risk of discontinuation‑syndrome symptoms than paroxetine, fluvoxamine, and sertraline, making tapering easier for most patients. 9

The American Family Physician recommends escitalopram as the preferred SSRI for older adults with depression, while advising avoidance of paroxetine and fluoxetine because of their higher adverse‑effect rates in this age group. 9
In elderly patients, escitalopram’s favorable side‑effect profile is especially valuable given age‑related pharmacokinetic changes and the common presence of polypharmacy. 9
Clinical guidance cautions against initiating paroxetine or fluoxetine in older adults due to markedly higher rates of adverse effects. 9

For breastfeeding mothers, paroxetine and sertraline are most frequently prescribed because they result in lower infant plasma concentrations; escitalopram remains an acceptable alternative when other agents are unsuitable. 10

Sexual dysfunction affects roughly 40 % of patients on SSRIs; escitalopram is associated with similar or slightly lower rates of sexual side effects compared with paroxetine, but higher rates than the non‑SSRI antidepressant bupropion. 10
When sexual dysfunction is a primary concern, switching to bupropion (which is not an SSRI) is recommended to improve tolerability. 10

Escitalopram should be monitored for QT‑interval prolongation, particularly at doses > 20 mg daily in adults > 60 years, consistent with the FDA boxed warning that also applies to citalopram. 10